Breaking News
February 18, 2019 - How Inactivity and Junk Food Can Harm Your Brain
February 18, 2019 - Diabetes tops common conditions for frequent geriatric emergency patients
February 18, 2019 - Longer-lived sperm produces offspring with healthier lifespans
February 18, 2019 - New dental adhesive prevents tooth decay around orthodontic brackets
February 18, 2019 - New eHealth tool shows potential to improve quality of asthma care
February 18, 2019 - New Australian initiative helps emergency clinicians to improve patient care
February 17, 2019 - Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 17, 2019 - Researchers identify faulty ‘brake’ that interferes with heart muscle’s ability to contract and relax
February 17, 2019 - Support from trusted adults can reduce risk of dying in suicidal teens, finds study
February 17, 2019 - Heart attack awareness improved since 2008
February 17, 2019 - Exercise gives a better brain boost to older men than women
February 17, 2019 - New research disproves previous assumptions of how looks influence personality
February 17, 2019 - Cannabis use as a teenager linked to depression later in life
February 17, 2019 - Sinks by Toilets in ICU Patient Rooms Harbor Harmful Bacteria
February 17, 2019 - Cancer cells’ plasticity makes them harder to stop
February 17, 2019 - Young cannabis users have increased risk of depression and suicidal behavior
February 17, 2019 - Tasmanian Devils Likely to Survive Cancer Scourge
February 17, 2019 - Neoadjuvant PD-1 blockade seems effective in glioblastoma
February 17, 2019 - Personal, social factors play role in enabling sustainable return to work after ill health
February 17, 2019 - Mouse studies show ‘inhibition’ theory of autism wrong
February 17, 2019 - Study shows how neuroactive steroids inhibit activity of pro-inflammatory proteins
February 17, 2019 - Use of liver grafts from older donors decreased despite better outcomes in recipients
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - Promising drug developed to rejuvenate muscle cells
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
First photoactive drug to fight Parkinson’s disease

First photoactive drug to fight Parkinson’s disease

image_pdfDownload PDFimage_print
First photoactive drug to fight Parkinson’s disease
Credit: Universidad de Barcelona

An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson’s disease, according to the new article in Journal of Controlled Release.

This compound, which proved effective in laboratory animals in vivo, has been carried out by a team led by Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, and collaborators.

Optopharmacology: beyond the limits of conventional drugs

Parkinson’s is the second most common neurodegenerative disease after Alzheimer’s and it affects more than 1 percent of the population. This disease, which affects the central nervous system, affects more than six million people worldwide, figures that could go higher than twelve million by 2030, according to data from the World Health Organization (WHO). In this disease, the neurotransmitter that controls the motor activity, dopamine, is reduced due the progressive death of dopaminergic neurons.

The action of conventional drugs is sometimes limited due several factors –lack of spatial specificity, slow and inaccurate distribution, etc.- which can reduce its therapeutic efficiency. Also, the efficiency of the traditional treatment on Parkinson’s (levodopa) diminishes over time and it requires to increase the administration of the dose or to change the drug. The adverse effects of new drugs (uncontrolled movements in the body, motor fluctuations, etc.) are another common denominator in most patients.

Optopharmacology is an innovative discipline based on the use of light –with a certain wave length- to control the activity of drugs. Therefore, light-sensitive drugs can act with a higher spatial and time precision and without creating adverse effects in the body.

MRS7145: opening the way to treat neurodegenerative diseases

The MRS7145, the first potentially therapeutic photoactive drug to fight Parkinson’s, is a photo-sensitive derivate from SCH442416, a selective antagonist of adenosine A2A receptor. In scientific bibliography, some A2A antagonist receptors came up as potential drugs to fight Parkinson’s, since they take part in the involved mechanisms in controlling the movement.

This photoactive drug is an inactive chemical compound that gets activated with light from a visible spectrum (with a 405 nm wave length) which is not harmful for the body. A series of optical fibers –planted in the striated bodies of laboratory animals- provide the irradiation of this area in the brain, which is responsible for the control of motor activity.

Lecturer Francisco Ciruela says, “once the striated body is radiated with violet light the active drug is released and blocks the adenosine A2A receptor. The blocking of adenosine receptors has an administrating effect on the activity of dopamine (pro-dopaminergic action).”

Photo-sensitive molecules that improve patients’ quality of life

Improving the spatial and temporary precision of the drug and strengthening the commitment of the patient to the therapy are some of the benefits of optopharmacology in Parkinson’s. “A fine time-space precision will enable manipulating the neural circuits in detail and set the functioning of those with therapeutic and neuroprotective purposes,” says Ciruela.

“Nowadays, in addition, there are treatments that are based on the implementation of electrodes in the brain of patients with Parkinson’s to control the electric activity of neurons. In the same lines, optical fibers could make light getting to almost any part of the body (spatial resolution), and these organs would be radiated with light controlled by an electronic device that would regulate the intensity and length of radiation (time resolution).

Maintaining the commitment of patients to the set therapeutic guideline on the long run is a big challenge for chronic diseases. “With a slow release system from the photoactive drug, such as a coupled patch with a radiation system remotely controlled by a phone App, the doctor could control in a precise manner the release of the most efficient dose of the active drug in the place of action,” says Ciruela.

Although the clinical application of this photoactive drug in patients is still far, this pharmacological innovation could lead the way to a research on new therapeutical solutions for this chronic disease. The new article, published in Journal of Controlled Release, is therefore a step forward in the field of pharmacology to design new therapeutical strategies with photo-sensitive molecules and to set innovative clinical protocols to improve patients’ quality of life.


Explore further:
First photoactive drug for pain treatment

More information:
Jaume Taura et al. Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist, Journal of Controlled Release (2018). DOI: 10.1016/j.jconrel.2018.05.033

Journal reference:
Journal of Controlled Release

Provided by:
University of Barcelona

Tagged with:

About author

Related Articles